$890.05
+2.34%Oct 15, 2026, 05:00 UTC
ARGENX SE announced that it will host a conference call and audio webcast on October 22, 2026, to discuss its third-quarter financial results and provide a business update.
Source:Oct 9, 2026, 14:35 UTC
ARGENX SE shares fell 12%.
Oct 8, 2026, 20:34 UTC
SueWallSt notified investors of a pending investigation into ARGENX SE.
Source:Oct 8, 2026, 14:02 UTC
Argenx shares fell 13% Thursday morning.
Oct 8, 2026, 14:02 UTC
Argenx reported that Vyvgart did not outperform placebo in a Phase 3 trial in patients with Sjögren’s disease.
Source:Oct 8, 2026, 10:13 UTC
ARGENX SE shares fell 18%, wiping out their year-to-date gains.
Source:Oct 8, 2026, 05:00 UTC
ARGENX SE announced plans to advance FB102 into Phase 3 development.
Source:Oct 8, 2026, 05:00 UTC
ARGENX SE announced positive topline results from its Phase 2 study of FB102 in adults with celiac disease, reporting that the study met its primary endpoint for change from baseline in the Vh:Cd ratio (p=0.0176).
Oct 8, 2026, 05:00 UTC
ARGENX SE announced that it will discontinue the Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease following an independent monitoring committee's recommendation to stop for futility.
Oct 7, 2026, 16:01 UTC
Halozyme expanded its ENHANZE collaboration and licensing agreement with ARGENX SE to cover eight targets, creating eligibility for additional milestone payments and royalties.
Source:Sep 29, 2026, 12:00 UTC
argenx SE will present new clinical, long-term and real-world data for VYVGART in myasthenia gravis and CIDP, plus results for empasiprubart and adimanebart, at the 2026 AANEM Annual Meeting and MGFA Scientific Session in Orlando, Florida, from September 29 to October 2, 2026.
Aug 27, 2026, 12:50 UTC
argenx completed its acquisition of Forte Biosciences, Inc., adding the anti-CD122 antibody FB102 to its immunology pipeline.
Source:Aug 21, 2026, 06:27 UTC
Argenx announced successful trial results for its biotech product, causing its stock to soar.
Source:Aug 17, 2026, 05:00 UTC
argenx announced positive topline results from the Phase 3 ALKIVIA trial of VYVGART Hytrulo (efgartigimod) in autoimmune myositis, meeting its primary endpoint of mean Total Improvement Score at Week 52 in combined IMNM and DM patients (p=0.0011).
Jul 27, 2026, 05:00 UTC
argenx agreed to acquire Forte Biosciences for $77 per share in cash, representing a total equity value of approximately $2.2 billion.
Jul 23, 2026, 05:41 UTC
Argenx expanded Vyvgart's label in the United States to cover all gMG serotypes during Q2 2026.
Source:Jul 23, 2026, 05:41 UTC
Argenx reported Q2 2026 financial results with Vyvgart sales of $1.516 billion, up 60% year-over-year.
Jun 10, 2026, 13:11 UTC
The FDA expanded the label of argenx's drug Vyvgart to include adult patients with generalized myasthenia gravis regardless of antibody status.
Source: